Concert Pharmaceuticals
Dr. Nabil Uddin joined Concert in 2014 and currently serves as Vice President, Corporate Development. He has over 15 years of experience in the biotech industry encompassing program and portfolio management and business development roles with a particular emphasis on CNS disorders and rare diseases. Prior to joining Concert, Dr. Uddin worked at Seaside Therapeutics, a company focused on neurodevelopmental disorders such as Fragile X Syndrome and autism spectrum disorders. He earned a BSc. in Biology from McMaster University, a Pharm.D. from the Massachusetts College of Pharmacy, and completed a post-doctoral fellowship at the University of North Carolina at Chapel Hill.
This person is not in any teams
This person is not in any offices
Concert Pharmaceuticals
Concert Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs.